IPSEN (OTCMKTS:IPSEY) Short Interest Update

by · The Cerbat Gem

IPSEN (OTCMKTS:IPSEY – Get Free Report) saw a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 37 shares, a decrease of 92.8% from the May 14th total of 514 shares. Based on an average trading volume of 2,616 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

IPSEN Stock Performance

OTCMKTS:IPSEY remained flat at $46.75 on Tuesday. 339 shares of the company’s stock traded hands, compared to its average volume of 744. IPSEN has a 52-week low of $28.66 and a 52-week high of $51.10. The firm’s 50-day simple moving average is $47.94 and its two-hundred day simple moving average is $42.84.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. HC Wainwright assumed coverage on shares of IPSEN in a report on Friday. They issued a “buy” rating on the stock. Finally, Zacks Research upgraded shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

View Our Latest Report on IPSEN

About IPSEN

(Get Free Report)

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

Featured Stories